Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
NASDAQ:TBPH
Total Valuation
Theravance Biopharma has a market cap or net worth of $898.42M. The enterprise value is $472.77M.
Market Cap$898.42M
Enterprise Value$472.77M
Share Statistics
Theravance Biopharma has 50,672,432 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding50,672,432
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Theravance Biopharma’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -17.84%.
Return on Equity (ROE)-0.32
Return on Assets (ROA)-0.16
Return on Invested Capital (ROIC)-17.84%
Return on Capital Employed (ROCE)-0.15
Revenue Per Employee663.72K
Profits Per Employee-581.63K
Employee Count97
Asset Turnover0.18
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Theravance Biopharma is 31.5. Theravance Biopharma’s PEG ratio is -0.54.
PE Ratio31.5
PS Ratio7.14
PB Ratio2.62
Price to Fair Value2.62
Price to FCF-38.73
Price to Operating Cash Flow3.74
PEG Ratio-0.54
Income Statement
In the last 12 months, Theravance Biopharma had revenue of 64.38M and earned -56.42M in profits. Earnings per share was -1.15.
Revenue64.38M
Gross Profit64.38M
Operating Income-46.95M
Pretax Income-44.61M
Net Income-56.42M
EBITDA-38.45M
Earnings Per Share (EPS)-1.15
Cash Flow
In the last 12 months, operating cash flow was 243.70M and capital expenditures -224.00K, giving a free cash flow of 243.48M billion.
Operating Cash Flow243.70M
Free Cash Flow243.48M
Free Cash Flow per Share4.80
Dividends & Yields
Theravance Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.95
52-Week Price Change84.50%
50-Day Moving Average14.81
200-Day Moving Average11.55
Relative Strength Index (RSI)64.86
Average Volume (3m)401.43K
Important Dates
Theravance Biopharma upcoming earnings date is Mar 2, 2026, Before Open (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateMar 2, 2026
Ex-Dividend Date―
Financial Position
Theravance Biopharma as a current ratio of 5.02, with Debt / Equity ratio of 19.17%
Current Ratio5.02
Quick Ratio5.02
Debt to Market Cap0.00
Net Debt to EBITDA-0.31
Interest Coverage Ratio-18.44
Taxes
In the past 12 months, Theravance Biopharma has paid 11.80M in taxes.
Income Tax11.80M
Effective Tax Rate-0.26
Enterprise Valuation
Theravance Biopharma EV to EBITDA ratio is -12.27, with an EV/FCF ratio of -39.75.
EV to Sales7.33
EV to EBITDA-12.27
EV to Free Cash Flow-39.75
EV to Operating Cash Flow-40.89
Balance Sheet
Theravance Biopharma has $329.68M in cash and marketable securities with $33.68M in debt, giving a net cash position of $296.00M billion.
Cash & Marketable Securities$329.68M
Total Debt$33.68M
Net Cash$296.00M
Net Cash Per Share$5.84
Tangible Book Value Per Share$3.59
Margins
Gross margin is 75.11%, with operating margin of -72.92%, and net profit margin of -87.63%.
Gross Margin75.11%
Operating Margin-72.92%
Pretax Margin-69.30%
Net Profit Margin-87.63%
EBITDA Margin-59.73%
EBIT Margin-65.34%
Analyst Forecast
The average price target for Theravance Biopharma is $25.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$25.60
Price Target Upside44.39% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast27.12%
EPS Growth Forecast―